Public Employees Retirement Association of Colorado Sells 478 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Public Employees Retirement Association of Colorado lessened its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 0.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,146 shares of the medical instruments supplier’s stock after selling 478 shares during the period. Public Employees Retirement Association of Colorado owned 0.08% of West Pharmaceutical Services worth $19,482,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of WST. Benjamin F. Edwards & Company Inc. boosted its stake in West Pharmaceutical Services by 8.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,366 shares of the medical instruments supplier’s stock worth $450,000 after acquiring an additional 106 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of West Pharmaceutical Services by 11.7% in the 2nd quarter. Hsbc Holdings PLC now owns 186,718 shares of the medical instruments supplier’s stock worth $61,727,000 after purchasing an additional 19,561 shares in the last quarter. Blair William & Co. IL grew its stake in shares of West Pharmaceutical Services by 10.5% in the 2nd quarter. Blair William & Co. IL now owns 112,520 shares of the medical instruments supplier’s stock worth $37,063,000 after buying an additional 10,654 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. increased its position in West Pharmaceutical Services by 3.4% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 8,507 shares of the medical instruments supplier’s stock valued at $2,802,000 after buying an additional 278 shares in the last quarter. Finally, Sargent Investment Group LLC purchased a new position in West Pharmaceutical Services during the second quarter valued at $237,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 1.0 %

NYSE WST opened at $308.15 on Friday. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The stock’s fifty day moving average price is $303.67 and its 200-day moving average price is $337.77. The stock has a market cap of $22.45 billion, a P/E ratio of 40.65, a P/E/G ratio of 10.58 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period last year, the company posted $2.11 earnings per share. As a group, equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at approximately $443,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.53% of the stock is owned by insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.